Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Pamela Cohen"'
Autor:
Aaron Scott, Manish Patel, Julie Bauman, Jeffrey Clarke, Howard Burris, Justin Gainor, Martin Gutierrez, Daniel Cho, Ricklie Julian, Pamela Cohen, Joshua Frederick, Celine Robert-Tissot, Honghong Zhou, Kinjal Mody, Karen Keating, Robert Meehan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/c629be3a7f774c30a5a88a7f86a82a58
Autor:
Antonio Jimeno, Robert S. Meehan, Sima Zacharek, Todd M. Bauer, Khanh Tu Do, Salomon M. Stemmer, Patricia LoRusso, Ravit Geva, Honghong Zhou, Ryan J. Sullivan, Pamela Cohen, Joshua Frederick, Manish R. Patel, Andressa S. Laino, Ding Wang, William Randolph, Corinne Maurice-Dror, Jing Sun
Publikováno v:
Journal of Clinical Oncology. 38:3092-3092
3092 Background: mRNA-2752 is a novel mRNA-based therapeutic agent encoding OX40L T cell co-stimulator, IL-23 and IL-36γ pro-inflammatory cytokines. Here we present findings from a first-in-human study of iTu mRNA-2752 in solid tumor patients as mon
Autor:
Pamela Cohen Kalafut, Jonathan Low
Publikováno v:
Strategy & Leadership. 29:9-15
There is increasing recognition of the importance of intangible assets. There is also a pressing need for a set of widely accepted metrics by which corporate leaders and the investment community can account for the non‐financial factors that affect
Publikováno v:
Journal of Ship Production. 15:164-178
There is both the need and opportunity to create an environment to share knowledge that will help the maritime industry grow and compete. Technology helps break away from traditional education, which is both synchronous and location-dependent. The fr
Autor:
Pamela, Cohen
Publikováno v:
EMS magazine. 37(10)
Autor:
Ayalew Tefferi, Pamela Cohen, Animesh Pardanani, Claudia Lebedinsky, Frank Neumann, Claire N. Harrison, Jorge E. Cortes, Francisco Cervantes, Francesco Passamonti
Publikováno v:
Journal of Clinical Oncology. 30:TPS6639-TPS6639
TPS6639 Background: SAR302503 is an orally administered selective JAK-2 inhibitor being evaluated for the treatment of MF. In a phase 1 study, SAR302503 reduced spleen size and disease-related symptoms and provided clinical benefit, including a reduc
Autor:
Jason Gotlib, Andrea Linder, Cem Akin, Pamela Cohen, Daniel J. DeAngelo, Sylvia Quesada, Alisa Ruddell, Timothy A. Graubert, Tracy I. George
Publikováno v:
Blood. 108:3609-3609
Background: Advanced forms of systemic mastocytosis (aggressive systemic mastocytosis [ASM] and mast cell leukemia [MCL]) are myeloproliferative disorders with few treatment options and a poor prognosis. In the majority of patients (pts), the pathoge
Autor:
Kalafut, Pamela Cohen, Low, Jonathan
Publikováno v:
Strategy & Leadership. 2001, Vol. 29 Issue 5, p9. 7p. 1 Diagram.
Autor:
Johannes Roesel, Pamela Cohen, Florian Heidel, C. Huber, Thomas Kindler, Virginia M. Klimek, Eli Estey, Thomas Fischer, Richard Stone, Eric J. Feldman, D. DeAngelo, H.-M. Thiede, Frank Breitenbuecher, Fian K. Solem, Birgit Carius, Gary J. Schiller, Francis J. Giles, Stephen D. Nimer, G. Ehninger
Publikováno v:
Blood. 104:454-454
The FLT3 receptor tyrosine kinase is expressed in 70-90% of cases of AML. Up to 35% of patients with AML show mutations in the JM-region or kinase domain of FLT3. These lead to autophosphorylation promoting ligand-independent cell proliferation and i
Autor:
Pamela Cohen, Charles A. Schiffer, Gary J. Schiller, Richard Yu, Yanfeng Wang, Lei Zhang, Gerhard Ehninger, Ronald Paquette, Richard Stone, Hagop M. Kantarjian, Jorge E. Cortes, D. DeAngelo, Penny E. Phillips, Thomas M. Fischer, Francis J. Giles
Publikováno v:
Blood. 104:262-262
Activating mutations in FLT3 (fms-like tyrosine kinase), either an ITD (repeat of 3–33 amino acids in the juxtamembrane region) or a point mutation in the activation loop, occur in blasts from 30% of AML patients, are associated with poor prognosis